Investing.comDoubao · 实盘不做把握 8/10不做原因:证据不足
北京时间·🕒 发布 09:40:31·⟳ 抓取 09:40:59 +28s·⚡ 决策 10-09 09:42:28 +1m29s·18.7 天前
临床期生物科技公司 Retension Pharmaceuticals 以每股12美元定价IPO，募资约4500万美元，代码RTSN登陆纳斯达克
唯一直接标的RTSN为当日新上市的临床期微盘生物科技股，没有价格历史、可比估值或本次事件对应的临床数据增量；IPO定价/挂牌是预期内的常规资本动作，首日涨跌由情绪和分配主导，无法建立正期望的事件驱动交易，也不存在可映射的供应链或同业标的。
📄 原文Investing.com↗ 原文
Retension Pharmaceuticals prices IPO at $12 per share
By Investing.com Advertisement Advertisement Retension Pharmaceuticals prices IPO at $12 per share Company News Publish…
不做 Retension Pharmaceuticals Inc.（RTSN.US）
首日新上市的无收入临床期微盘股，IPO定价为预期内常规动作、无临床数据或审批增量，缺少价格历史与可锚定先例，首日方向纯由情绪主导，无正期望事件edge；亦无供应链或同业可映射标的。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Retension以12美元定价、募资约4500万美元并以RTSN首日挂牌，但这是无收入临床期公司的常规IPO，缺乏数据/审批类基本面催化与可锚定的价格，首日交易纯属投机，故回避。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- IPO定价与挂牌是注册流程内的预期动作，不构成超预期的基本面增量。
- 公司无营收、核心价值取决于尚未读出的RTN-001二期数据，当前无法量化业绩或估值弹性。
主要风险
- 新股首日可能因低流通盘和稀缺性大幅波动，但方向不可预测，追高易见光死。
- 临床期微盘股流动性与融资存续风险高，后续可能折价再融资。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
公司为无营收临床期发行人，资产价值高度依赖未读出的RTN-001，叠加新股摊薄与微盘流动性风险，缺乏支持追多的证据。
检索:Retension Pharmaceuticals RTSN IPO insider selling clinical risk downside
先例如何影响了这次决策
对本次决策的影响:先例空缺与缺乏基本面催化共同支持回避，而非以小仓试探参与首日炒作。
方向:无针对该新上市主体的可用先例；新股首日表现受配售与情绪支配，不构成方向或胜率依据。
涨幅量级:缺乏同主体、同相位且锚定干净的对齐样本，无法校准幅度，因此不设止盈止损。
形态:临床期微盘生物科技IPO虽常见首日溢价与后续回落的高波动模式，但无具体首发锚点支撑，不用于本笔定量。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`retension pharmaceuticals 3,750,000 shares $45 million nasdaq capital market | retension pharmaceuticals rtsn ipo pricing $12 per share | rtn-001 hypertension phase 2b ipo october `；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 7,183 字
Retension Pharmaceuticals prices IPO at $12 per share By Investing.com
Advertisement
Advertisement
Retension Pharmaceuticals prices IPO at $12 per share
Company News
Published
Oct 08, 2026, 09:40 PM
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
© Reuters
In this article:
RTSN
0.00%
FALLS CHURCH, Va. -
Retension Pharmaceuticals
Inc. (
NASDAQ:RTSN
) announced Wednesday the pricing of its initial public offering of 3,750,000 shares of common stock at $12.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company expects to receive gross proceeds of $45.0 million before deducting underwriting discounts, commissions and other offering expenses. Retension granted underwriters a 30-day option to purchase up to an additional 562,500 shares at the initial public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about October 13, 2026, subject to customary closing conditions. The shares are expected to begin trading today on the Nasdaq Capital Market under the ticker symbol RTSN.
Retension stated it intends to use the net proceeds, together with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for the planned Phase 3 clinical trial of RTN-001. The remainder will be used for general corporate purposes and other operating expenses.
The company focuses on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Titan Partners is acting as lead manager.
Registration statements relating to the securities became effective on October 8, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,306.70
+75.0
+0.15%
US 500
7,776.70
+11.2
+0.14%
Dow Jones
51,231.64
+51.77
+0.10%
S&P 500
7,765.36
-36.41
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.805
-0.125
-0.12%
Crude Oil WTI Futures
90.84
-0.65
-0.71%
Brent Oil Futures
103.45
-0.83
-0.80%
Natural Gas Futures
3.133
-0.037
-1.17%
Gold Futures
4,196.55
+39.55
+0.95%
Silver Futures
60.265
+0.845
+1.42%
Copper Futures
6.6205
+0.0505
+0.77%
US Soybeans Futures
1,296.00
+8.50
+0.66%
U.S. 10Y
5.219
-0.010
-0.19%
U.S. 30Y
5.605
-0.002
-0.04%
U.S. 5Y
4.98
-0.011
-0.22%
U.S. 3M
4.161
+0.010
+0.24%
US 10Y T-Note Futures
104.77
+0.05
+0.04%
Euro Bund Futures
121.23
+0.56
+0.46%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SNDK
1,609.46
-4.90%
9.36M
AMD
620.68
-3.90%
23.49M
INTC
107.08
-5.34%
120.20M
AAPL
340.42
+1.11%
35.33M
META
720.89
-0.06%
16.04M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.47M
CMG
32.68
+6.21%
72.04M
GDDY
103.19
+6.15%
1.83M
ACN
208.36
+5.96%
12.10M
IT
195.41
+5.19%
919.83K
CTSH
60.01
+5.15%
9.93M
EPAM
113.86
+5.11%
847.63K
Name
Last
Chg. %
Vol.
ALAB
347.05
-9.21%
6.45M
CRWV
81.58
-7.77%
42.32M
NBIS
219.71
-7.35%
21.97M
ARM
275.29
-6.48%
6.20M
GLW
152.83
-6.38%
9.05M
VST
156.14
-6.35%
11.32M
LITE
1,048.60
-5.62%
4.88M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SPCX
160.57
-4.19%
71.90M
SNDK
1,609.46
-4.90%
9.36M
PLTR
198.78
+2.40%
41.87M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Retension Pharmaceuticals prices IPO at $12 per share
Company News
Published
Oct 08, 2026, 09:40 PM
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
© Reuters
In this article:
RTSN
0.00%
FALLS CHURCH, Va. -
Retension Pharmaceuticals
Inc. (
NASDAQ:RTSN
) announced Wednesday the pricing of its initial public offering of 3,750,000 shares of common stock at $12.00 per share, according to a press release statement.
The clinical-stage biopharmaceutical company expects to receive gross proceeds of $45.0 million before deducting underwriting discounts, commissions and other offering expenses. Retension granted underwriters a 30-day option to purchase up to an additional 562,500 shares at the initial public offering price, less underwriting discounts and commissions.
The offering is expected to close on or about October 13, 2026, subject to customary closing conditions. The shares are expected to begin trading today on the Nasdaq Capital Market under the ticker symbol RTSN.
Retension stated it intends to use the net proceeds, together with existing cash and cash equivalents, to complete the Phase 2b clinical trial of RTN-001 in uncontrolled hypertension and to prepare for the planned Phase 3 clinical trial of RTN-001. The remainder will be used for general corporate purposes and other operating expenses.
The company focuses on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension.
Leerink Partners, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Titan Partners is acting as lead manager.
Registration statements relating to the securities became effective on October 8, 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Retension Pharmaceuticals prices IPO at $12 per share
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,306.70
+75.0
+0.15%
US 500
7,776.70
+11.2
+0.14%
Dow Jones
51,231.64
+51.77
+0.10%
S&P 500
7,765.36
-36.41
-0.47%
Nasdaq
27,193.34
-345.35
-1.25%
S&P 500 VIX
15.41
+0.33
+2.19%
Dollar Index
101.805
-0.125
-0.12%
Crude Oil WTI Futures
90.84
-0.65
-0.71%
Brent Oil Futures
103.45
-0.83
-0.80%
Natural Gas Futures
3.133
-0.037
-1.17%
Gold Futures
4,196.55
+39.55
+0.95%
Silver Futures
60.265
+0.845
+1.42%
Copper Futures
6.6205
+0.0505
+0.77%
US Soybeans Futures
1,296.00
+8.50
+0.66%
U.S. 10Y
5.219
-0.010
-0.19%
U.S. 30Y
5.605
-0.002
-0.04%
U.S. 5Y
4.98
-0.011
-0.22%
U.S. 3M
4.161
+0.010
+0.24%
US 10Y T-Note Futures
104.77
+0.05
+0.04%
Euro Bund Futures
121.23
+0.56
+0.46%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
340.42
+3.75
+1.11%
NVDA
230.48
-6.99
-2.94%
GOOGL
348.29
-2.21
-0.63%
TSLA
375.00
-2.81
-0.74%
AMZN
254.06
-5.86
-2.25%
NFLX
71.57
+1.87
+2.68%
META
720.89
-0.42
-0.06%
Advertisement
Most Popular Articles
News
Analysis
Nasdaq ends over 1% lower as tech stocks take a hit on OpenAI revenue report
By Investing.co
...
Oct 09, 2026
Oil settles below session high after Trump says no Iran attack before midterms
By Investing.co
...
Oct 09, 2026
Citi names 5 top chip picks ahead of Q3 earnings
By Investing.co
...
Oct 08, 2026
Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
By Investing.co
...
Oct 08, 2026
Why Citi says the Fed could be setting up for a dovish surprise
By Investing.co
...
Oct 08, 2026
TSMC Blowout Earnings: What This Means for Markets
By Lee Yang
Oct 09, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Oil Tops $100 as Stocks Come Under Pressure - Dow’s 50,000 Level Now in Focus
By Fawad Razaqz
...
Oct 08, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SNDK
1,609.46
-4.90%
9.36M
AMD
620.68
-3.90%
23.49M
INTC
107.08
-5.34%
120.20M
AAPL
340.42
+1.11%
35.33M
META
720.89
-0.06%
16.04M
Name
Last
Chg. %
Vol.
CSGP
29.81
+8.01%
9.47M
CMG
32.68
+6.21%
72.04M
GDDY
103.19
+6.15%
1.83M
ACN
208.36
+5.96%
12.10M
IT
195.41
+5.19%
919.83K
CTSH
60.01
+5.15%
9.93M
EPAM
113.86
+5.11%
847.63K
Name
Last
Chg. %
Vol.
ALAB
347.05
-9.21%
6.45M
CRWV
81.58
-7.77%
42.32M
NBIS
219.71
-7.35%
21.97M
ARM
275.29
-6.48%
6.20M
GLW
152.83
-6.38%
9.05M
VST
156.14
-6.35%
11.32M
LITE
1,048.60
-5.62%
4.88M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,035.84
-4.79%
29.91M
NVDA
230.48
-2.94%
118.70M
SPCX
160.57
-4.19%
71.90M
SNDK
1,609.46
-4.90%
9.36M
PLTR
198.78
+2.40%
41.87M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
11c0b93a4e· 2026-10-09 09:42 · doubao / doubao-seed-evolving-latest-version · 策略包d5018cb8913f当前